Leht 1 alates 33 tulemused
FIELD OF INVENTION
The present invention relates to the treatment of pathologies and diseases that are inflammatory in nature. The treatment is practiced by the administration of des-aspartate-angiotensin I or its derivatives to a subject in need of such a treatment. The present invention further
FIELD OF THE INVENTION
The present invention relates to compositions and methods for the treatment and prevention of cancer. More specifically, the present invention relates to the use of angiotensin-(1-7) or other agonists for the angiotensin-(1-7) receptor as anticancer
FIELD OF THE INVENTION
The present invention relates to compositions and methods for the treatment and prevention of cancer. More specifically, the present invention relates to the use of angiotensin-(1-7) or other agonists for the angiotensin-(1-7) receptor as anticancer
INTRODUCTION
1. Technical Field
The technical field of this invention concerns the identification and cloning of an angiotensin II type 2 receptor, a peptide hormone receptor involved in growth and differentiation, and the use of this novel receptor in the diagnosis and treatment of cardiovascular
FIELD OF THE INVENTION
This present invention relates to compositions and methods useful for the inhibition of tumor cell proliferation.
BACKGROUND OF THE INVENTION
Despite many years of promising new therapies, cancer remains a major cause of morbidity and mortality (Bailar et al., N. Engl. J. Med.
TECHNICAL FIELD
The present invention provides a novel approach to cancer diagnosis and cancer therapy. In particular, the identification and specific targeting of cancer stem cell populations present in a tumour to eradicate or slow or prevent tumour growth and spread, including the potential for
BACKGROUND OF THE INVENTION
In the article by Leonardo A. Fernandez et al. entitled Renin-Angiotensin and Development of collateral Circulation After Renal Ischemia, Am.J. Physiol. 243 (Hart, Circ. Physiol. 12) H869-H875, 1982, it is reported that the infusion of angiotensin-II to aortic-ligated
This application is a 371 of International Application No. PCT/AT2009/000136, filed 7 Apr. 2009, which claims priority to A566/2008, filed 9 Apr. 2008, all of which are herein incorporated by reference in their entireties.
The invention relates to the treatment of tumours.
According to information
STATEMENT REGARDING SEQUENCE LISTING
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is
This application is the U.S. national phase of international application PCT/BR02/00156 filed in English on 05 Nov. 2002, which designated the U.S. PCT/BR02/00156 claims priority to BR Application No. PI 0105509-7 filed 05 Nov. 2001. The entire contents of these applications are incorporated herein
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. National Stage filing of International Application Serial No. PCT/GB2003/003758 filed Aug. 21, 2003, which claims priority to GB 0219524.6 filed Aug. 21, 2002, each of which is incorporated herein by reference in its
FIELD OF THE INVENTION
The present invention relates to therapeutic uses of monoclonal antibodies to the angiotensin-II type-I receptor, in particular in the treatment of cancer and vascular smooth muscle cell proliferation.
BACKGROUND OF THE INVENTION
Angiotensin-II plays a central role in
FIELD OF THE INVENTION
This invention relates to novel heteroaryl non-peptidic compounds that mimic the heptapeptide angiotensin (1-7) [Ang(1-7)] and act as agonists of the Mas receptor, especially in a selective manner. The invention further relates to methods of using such compounds as therapeutic
BACKGROUND OF THE INVENTION
1. Field of the Invention
Embodiments of the invention disclosed herein relate generally to compositions and methods for altering hepatocyte growth factor activity or c-Met receptor activity. Certain aspects relate to the diagnosis, prevention or treatment of, as well as
FIELD OF THE INVENTION
This invention relates to novel heteroaryl non-peptidic compounds that mimic the heptapeptide angiotensin (1-7) [Ang(1-7)] and act as agonists of the Mas receptor, especially in a selective manner. The invention further relates to methods of using such compounds as therapeutic